Wall Street analysts forecast that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will report sales of $876.57 million for the current quarter, Zacks reports. Nine analysts have made estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $847.72 million to $900.89 million. Alexion Pharmaceuticals posted sales of $831.00 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.5%. The company is scheduled to issue its next earnings report on Thursday, February 15th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $876.57 million for the current year, with estimates ranging from $3.49 billion to $3.54 billion. For the next fiscal year, analysts forecast that the firm will report sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the business posted $1.23 EPS.

Several equities research analysts recently commented on ALXN shares. TheStreet downgraded Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price on the stock in a report on Tuesday, October 31st. Credit Suisse Group reiterated a “buy” rating and set a $166.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, December 12th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $130.00 target price (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $154.00.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up $1.77 during trading hours on Tuesday, hitting $124.48. The company had a trading volume of 4,150,000 shares, compared to its average volume of 2,090,000. The stock has a market cap of $27,810.00, a P/E ratio of 55.57, a P/E/G ratio of 1.03 and a beta of 1.17. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the sale, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.35% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Jennison Associates LLC grew its stake in Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Alexion Pharmaceuticals by 4,509.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after acquiring an additional 864,967 shares in the last quarter. USA Financial Portformulas Corp acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $3,632,000. IFC Holdings Incorporated FL acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $861,000. Finally, Chicago Equity Partners LLC acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $320,000. Hedge funds and other institutional investors own 94.27% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $876.57 Million” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/16/alexion-pharmaceuticals-inc-alxn-expected-to-announce-quarterly-sales-of-876-57-million-2.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.